Head-to-Head Comparison of 68Ga-PSMA-11 and 131I in the Follow-Up of Well-Differentiated Metastatic Thyroid Cancer: A New Potential Theragnostic Agent

Head-to-Head Comparison of 68Ga-PSMA-11 and 131I in the Follow-Up of Well-Differentiated Metastatic Thyroid Cancer: A New Potential Theragnostic Agent

IntroductionThyroid cancer is the main endocrine neoplasia worldwide, for which 131I therapy is the cornerstone treatment. One of the main problems of follow up in patients with this type of cancer, is the need for thyroglobulin stimulation, not to mention the poor availability of 123I or 124I, to p...

Full description

Bibliographic Details
Main Authors: Quetzali Pitalua-Cortes, Francisco Osvaldo García-Perez, Joel Vargas-Ahumada, Sofia Gonzalez-Rueda, Edgar Gomez-Argumosa, Eleazar Ignacio-Alvarez, Irma Soldevilla-Gallardo, Liliana Torres-Agredo
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-12-01
Series:Frontiers in Endocrinology
Subjects:
thyroid cancer
PSMA
iodine
theragnostic
PET
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2021.794759/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2021.794759/full

Similar Items